Zinforo is indicated in neonates, infants, children, adolescents and adult patients with the following infections (see Precautions and PHARMACOLOGY: Pharmacodynamics under Actions): Complicated skin and soft tissue infections (cSSTI); Community-acquired pneumonia (CAP).